Form D · Biotechnology

Cellebration Life Sciences, Inc.

Phoenix, AZ · CIK 0001863013

Offering snapshot reported Aug 21, 2023 · SEC filing

Reported sold
$2.8M
Offering amount: $20M
Investors reported
63
Form D · investor count
Minimum accepted
$25K
Reported outside-investor minimum
First sale
Jan 18, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.4M$2.8MJun 2, 2021: $285,000.00Jun 2, 2021May 31, 2022: $1,290,000.00May 31, 2022Jun 13, 2022: $1,290,000.00Aug 21, 2023: $2,804,527.00Aug 21, 2023

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$285,000 → $2,804,527

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 21, 2023Amendment$2,804,527$2,519,527vs Jun 2, 202163SEC filing
Jun 13, 2022Amendment$1,290,000$0vs May 31, 202214SEC filing
May 31, 2022Amendment$1,290,000$1,005,000vs Jun 2, 202114SEC filing
Jun 2, 2021Initial$285,000No comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06c
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-401437

Source: Form D, filed Aug 21, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Bill Deegan Director
Tim Kopatich Executive
Deven Patel Director
Anand Srivastava Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
12601 N. Cave Creek Road, Suite 111
Phoenix, AZ, 85022